Do recombinant-engineered nanoparticle vaccines hold promise for the prevention of respiratory syncytial virus?
During the 1960s, a formalin-inactivated RSV vaccine (FI-RSV) with alum adjuvant formulation was used to vaccinate young age children less than 6 months of age, which caused severe respiratory disease requiring hospitalizations and causing two deaths upon natural RSV infection (2). Since this tragic...
Saved in:
Published in | Nanomedicine (London, England) Vol. 11; no. 5; pp. 439 - 442 |
---|---|
Main Authors | , , |
Format | Journal Article |
Language | English |
Published |
England
Future Medicine Ltd
01.03.2016
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | During the 1960s, a formalin-inactivated RSV vaccine (FI-RSV) with alum adjuvant formulation was used to vaccinate young age children less than 6 months of age, which caused severe respiratory disease requiring hospitalizations and causing two deaths upon natural RSV infection (2). Since this tragic failure of FI-RSV vaccine trials due to vaccine-enhanced disease (VED) upon infection, there is no licensed vaccine against RSV. Some children and adults are re-infected every 3-10 years often with severe manifestation of sinus and/or asthma disease complications. [...]the major challenges for developing RSV vaccines include protection of young infants, inability of natural infection-induced immunity to prevent reinfection and notorious legacy of VED. Coexpression of RSV F or G and influenza virus M1 matrix protein in insect cells using the baculovirus expression system resulted in efficient release of VLPs presenting RSV F or G, which are effective in inducing Th1-type antibody responses and inhibiting lung viral replication in mice (14). [...]RSV F VLP immunization of mice induced CD8α+ DCs and IFN-γ producing CD8 T-cell responses in the lungs, preventing pulmonary histopathology of VED (18). [...]F VLP nanoparticle vaccination can induce distinct innate and adaptive cellular subsets preventing pulmonary VED in mice, which are different from FI-RSV vaccination and live RSV reinfections, after RSV challenge. |
---|---|
Bibliography: | SourceType-Other Sources-1 content type line 63 ObjectType-Editorial-2 ObjectType-Commentary-1 ObjectType-Article-3 |
ISSN: | 1743-5889 1748-6963 |
DOI: | 10.2217/nnm.16.2 |